HCD8MAG-15K

MILLIPLEX^® 人CD8+ T细胞磁珠板 - 免疫学多重检测

Name: MILLIPLEX<SUP>®</SUP> 人CD8+ T细胞磁珠板 - 免疫学多重检测
Brand: MM

Configurable Human CD8+ T Cell 17-Plex Panel

别名:

Human CD8 T cell cytokine panel, Human cytokine multiplex kit, Luminex^® human cytokine immunoassay, Millipore human cytokine panel

登录查看组织和合同定价。

关于此项目

UNSPSC Code:

12161503

NACRES:

NA.84

eCl@ss:

32161000

主要文件

查看所有文档

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

产品名称

MILLIPLEX^® 人CD8+ T细胞磁珠板 - 免疫学多重检测, Configurable Human CD8+ T Cell 17-Plex Panel

species reactivity

human

manufacturer/tradename

Milliplex^®

Quality Level

200

packaging

1 ea of

assay range

standard curve range: 0.4-1,500 pg/mL
(IL-6)
standard curve range: 0.5-2,000 pg/mL
(TNFα)
standard curve range: 1-3,500 pg/mL
(MIP-1α)
standard curve range: 1-5,000 pg/mL
(Granzyme B)
standard curve range: 1-5,000 pg/mL
(IFNγ)
standard curve range: 1-5,000 pg/mL
(IL-5)
standard curve range: 10-50,000 pg/mL
(Perforin)
standard curve range: 10-50,000 pg/mL
(sFasL)
standard curve range: 2-10,000 pg/mL
(IL-4)
standard curve range: 2-10,000 pg/mL
(sCD137)
standard curve range: 2-7,500 pg/mL
(IL-13)
standard curve range: 2-7,500 pg/mL
(IL-2)
standard curve range: 20-100,000 pg/mL
(Granzyme A)
standard curve range: 4-15,000 pg/mL
(GM-CSF)
standard curve range: 400-1,650,000 pg/mL
(sFas)
standard curve range: 5-20,000 pg/mL
(IL-10)
standard curve range: 7-30,000 pg/mL
(MIP-1β)

technique(s)

multiplexing: suitable

input

serum plasma (Cell culture, cell culture supernatants)

detection method

fluorometric (Luminex^® xMAP^® technology)

shipped in

wet ice

storage temp.

2-8°C

Biochem/physiol Actions

抗体与该面板中任何其他分析物之间的交叉反应性都为无法检测或可忽略。

Features and Benefits

通过在此面板中选择可用的分析物来设计多重试剂盒。

Preparation Note

试剂盒组分建议的存储温度为2-8°C。

Legal Information

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

General description

CD8+ T cells (also known as cytotoxic T cells, cytolytic T cells and killer T cells) belong to a sub-group of T cells capable of inducing the death of infected somatic or tumor cells. T cells that bind weakly to Major Histocompatibility Complex (MHC) self-antigens are positively selected into single-positive CD4+ or CD8+ T cells in the thymus. Those CD8+ T cells that survive and mature after activation become cytotoxic cells, expressing T-cell receptors (TCRs) capable of recognizing specific antigenic peptides bound to Class I MHC molecules and the glycoprotein CD8. Affinity between the CD8 protein and the MHC molecule helps to keep the cytotoxic T cell and target closely bound during antigen specific activation. Once activated, CD8+ T cells are generally classified as having a predefined cytotoxic role within the immune system and undergo IL-2 induced clonal expansion, which increases the number of cells specific for the target antigen. The CD8+ T cells then travel throughout the body in search of antigen-positive somatic/tumor cells.

Application

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 17 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: GM-CSF, sCD137, IFNγ, sFas, sFasL, Granzyme A, Granzyme B, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, MIP-1α, MIP-1β, TNF-α, Perforin

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

pictograms

GHS05,GHS07,GHS08,GHS09

signalword

Danger

hcodes

H302 + H312 + H332 - H317 - H318 - H373 - H411

pcodes

P273 - P280 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338 - P314

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

存储类别

10 - Combustible liquids

wgk

WGK 3

法规信息

新产品

此项目有

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Characterization of Surface Receptor Expression and Cytotoxicity of Human NK Cells and NK Cell Subsets in Overweight and Obese Humans.

Wiebke Naujoks et al.

Frontiers in immunology, 11, 573200-573200 (2020-10-27)

Obesity is associated with an increased risk for several cancer types and an altered phenotype and functionality of natural killer (NK) cells. This study aimed to investigate the association of overweight and obesity with NK cell functions and receptor expression

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28.

Chaoxu Zhang et al.

Frontiers in oncology, 10, 760-760 (2020-06-13)

Anti-PD-1 therapy has been approved for cancer treatment. However, the response rate is unsatisfactory. The expression of PD-L1 in tumor tissues is unreliable to predict the treatment response. Recent studies have suggested that exosomal PD-L1 not only exerts immunosuppressive effects

Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients.

Antti Hurme et al.

Frontiers in immunology, 13, 869990-869990 (2022-05-10)

The emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from spreading despite available vaccines. Reports of breakthrough infections and decreased capacity of antibodies to neutralize variants

Viral Kinetics of an Acute Hepatitis B Virus Subgenotype F1b Infection in a Mexican Subject.

Arturo Panduro et al.

Clinical liver disease, 19(2), 41-48 (2022-03-22)

Content available: Author Interview and Audio Recording.

Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins.

Emelie Foord et al.

Journal of immunology research, 2020, 7375947-7375947 (2020-08-25)

PD-1/PD-L1 blockade has revolutionized the field of immunooncology. Despite the relative success, the response rate to anti-PD-1 therapy requires further improvements. Our aim was to explore the enhancement of T-cell function by using novel PD-1-blocking proteins and compare with clinically

查看所有相关文献

MILLIPLEX® 人CD8+ T细胞磁珠板 - 免疫学多重检测